Core Insights - SINTX Technologies has published a peer-reviewed study demonstrating the antiviral efficacy of silicon nitride against various virus strains, including SARS-CoV-2 and MERS-CoV [1][2][4] Company Overview - SINTX Technologies is an advanced ceramics innovator specializing in biomedical applications of silicon nitride (Si₃N₄) and is the only FDA-cleared and ISO-certified silicon nitride manufacturer in the U.S. [3][5][10] - The company is transitioning from a single-product orthopedic implant manufacturer to a platform technology company with broad applications in infection control and medical devices [9] Study Findings - The study showed that alpha-phase silicon nitride (α-Si₃N₄) can reduce infectious SARS-CoV-2 titers by up to 99.97% within 10 minutes, with complete inactivation observed by 30 minutes [4] - When embedded in textile fabric, silicon nitride achieved 97% inactivation, demonstrating broad-spectrum virucidal activity against several SARS-CoV-2 variants and MERS-CoV [4] Market Opportunity - The global infection-prevention and control market is projected to exceed $230 billion by 2032, with the antiviral PPE market estimated to reach over $40 billion by 2030 and the global wound care market forecast to surpass $30 billion by 2030 [6] - SINTX believes its silicon nitride-based products can capture significant market share in these sectors due to their superior safety profile and performance compared to traditional metal-based antimicrobials [6] Advantages of Silicon Nitride - Unlike traditional antimicrobial additives like copper and silver, silicon nitride releases non-toxic reactive nitrogen species that damage viral RNA and proteins without harming surrounding tissue [7] - Potential applications include wound dressings, surgical sutures, face masks, hospital linens, and HEPA filters [8] Strategic Positioning - The publication of the study marks a strategic milestone for SINTX as it seeks partnerships and licensing opportunities to accelerate commercialization of its technology [9]

Core Insights - Sintx Technologies, Inc. announced the retirement of Dr. Sonny Bal as Chairman of the Board, with Eric Olson, the current CEO, appointed as the new Chairman effective immediately [1][2] Leadership Transition - Dr. Bal has been Chairman since 2015 and has significantly contributed to Sintx's transformation and growth in advanced materials [2] - Eric Olson expressed gratitude for Dr. Bal's leadership and emphasized the company's focus on high-value medical applications and strategic partnerships moving forward [3] - Since becoming CEO in August 2024, Olson has redirected the company towards high-growth opportunities in biomedical and medical device sectors [3] Company Overview - Sintx Technologies specializes in advanced ceramics for medical applications and is a leader in the research and manufacturing of silicon nitride, with products implanted in humans since 2008 [4] - The company has pursued strategic acquisitions and alliances to expand into new markets [4]

As filed with the Securities and Exchange Commission on February 7, 2023 Registration No. 333-269475 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SINTX Technologies, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 3841 84-1375299 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identificatio ...

As filed with the Securities and Exchange Commission on February 6, 2023 Registration No. 333-269475 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SINTX Technologies, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 3841 84-1375299 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 1885 West 2100 Sou ...